Price
No data yet.
Social Signal Score
Revenue
$17.50M-0.59%Company Profile
- CEO
- Tao Ling
- Sector
- Technology
- Industry
- Hardware, Equipment & Parts
- Employees
- 131
- Beta
- 0.57
- Country
- CN
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.04
Financials
Revenue
$17.50M-0.6%Net Income
$-4.75M-1400.6%EBITDA
$-2.72M-502.8%Free Cash Flow
$0.00EPS (diluted)
$-0.80-108.8%Shares Outstanding (diluted)
5.96M+14625.7%Operating Expenses
$5.38MCash & Debt
$1.80MRevenue by Segment (annual)
$4.89MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $39.68M | $-10.02M | $-4.38 |
| 2024 | $32.46M | $-10.06M | $-168.50 |
| 2023 | $57.53M | $-10.95M | $-1955.00 |
| 2022 | $105.42M | $199.0K | $1062.50 |
| 2021 | $167.74M | $3.10M | $14347.50 |
| 2020 | $140.07M | $2.71M | $50.00 |
| 2019 | $46.58M | $757.9K | $14.02 |
| 2018 | $61.46M | $495.3K | $9.18 |
Valuation
OSThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+33.33%Social Signal Score
Mentions (5)
- Newsnewsfilecorp.com·12d ago·Negative
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announce that the World Health Organization has approved the proprietary name 'Herlystic' was approved by the World Health Organization (WHO) a…
View source ↗ - Newsnewsfilecorp.com·19d ago·Negative
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial After successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize regulatory review with FDA and EMA CBER recently re-opened Project Orbis to foreign-sponsored U.S. companies only New York, New York and Rockville, Maryl…
View source ↗ - Newsnewsfilecorp.com·28d ago·Neutral
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) The two remaining patients who have not yet reached the 3-year timepoint from enrollment have trial monitoring visits scheduled for September 2026 and early October 2026 Company receives $3.15 mill…
View source ↗ - Newsnewsfilecorp.com·34d ago·Negative
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJapan Interim 3-year overall survival data, U.S. FDA Type C Statistical Methods meeting and U.K. MHRA Statistical Methods Scientific Advice Meeting expected in Septemb…
View source ↗ - Newsnewsfilecorp.com·54d ago·Negative
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival bene…
View source ↗
Insider trading
Open-market buys and sells by OST officers and directors.
No open-market trades in the recent filings. All 3 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
3 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OST.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.